Dupont Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Dupont Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-47,941	Closed	-$140K	–	1562
2020 Q2	$140K	Sell	47,941 -33,821	-41%	-$107K	﹤0.01%	1214
2020 Q1	$231K	Sell	81,762 -156,417	-66%	-$504K	0.01%	969
2019 Q4	$773K	Sell	238,179 -41,378	-15%	-$120K	0.02%	665
2019 Q3	$604K	Sell	279,557 -29,969	-10%	-$80.1K	0.01%	706
2019 Q2	$972K	Hold	309,526	–	–	0.02%	557
2019 Q1	$1.15M	Buy	309,526 +109,978	+55%	+$371K	0.03%	507
2018 Q4	$579K	Buy	+199,548	New	+$548K	0.01%	684
2014 Q2	–	Sell	-87,194	Closed	-$725K	–	725
2014 Q1	$725K	Sell	87,194 -51,170	-37%	-$439K	0.01%	553
2013 Q4	$1.17M	Sell	138,364 -206,857	-60%	-$1.74M	0.02%	480
2013 Q3	$2.75M	Sell	345,221 -110,310	-24%	-$887K	0.05%	302
2013 Q2	$3.52M	Buy	+455,531	New	+$3.55M	0.07%	260

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dupont Capital Management's PDLI Position: Q3 2020 in Review

Dupont Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 47,941 shares — an estimated $140K sold.

Dupont Capital Management first reported a position in PDLI in Q2 2013 and held it in 11 quarters. The position peaked at $3.52M in Q2 2013. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

Dupont Capital Management reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
Dupont Capital Management sold 47,941 PDL BioPharma, Inc. shares in Q3 2020, an estimated $140K.
Dupont Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 11 quarters.
Dupont Capital Management's PDL BioPharma, Inc. position peaked at $3.52M in Q2 2013.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Dupont Capital Management's 13F filing for Q3 2020, filed 29 Oct 2020.